Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 1, 2020.
Article Versions
- Latest version (July 1, 2019 - 04:00).
- You are currently viewing a Latest version of this article (February 1, 2020 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2020 The Journal of Rheumatology
Author Information
- Lucy O’Malley,
- Katie L. Druce,
- Dimitrios Chanouzas,
- Matthew D. Morgan,
- Rachel Jones,
- David R.W. Jayne,
- Neil Basu and
- Lorraine Harper
- From the Institute of Clinical Sciences, University of Birmingham, Birmingham; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester; Department of Medicine, University of Cambridge, Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals), which provided a research grant to cover the trial and mycophenolate mofetil costs for MYCYC and F. Hoffmann–La Roche, which provided the rituximab and a research grant that contributed to trial costs for RITUXVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR)/Wellcome Trust Clinical Research Facility (Birmingham, UK). The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health.
LH, DRJ, and RJ have received research grants and speaker fees from F. Hoffmann-La Roche. LH, RJ, DRJ, MDM have been involved in studies in which rituximab was given free of charge by Roche and MMF was given free of charge by Vifor Pharma.
L. O’Malley, MB ChB, Institute of Clinical Sciences, University of Birmingham; K.L. Druce, PhD, Arthritis Research UK Centre for Epidemiology, University of Manchester; D. Chanouzas, PhD, Institute of Clinical Sciences, University of Birmingham; M.D. Morgan, PhD, Institute of Clinical Sciences, University of Birmingham; R. Jones, MD, Department of Medicine, University of Cambridge; D.R. Jayne, MD, Department of Medicine, University of Cambridge; N. Basu, PhD, Institute of Infection, Immunity and Inflammation, University of Glasgow; L. Harper, PhD, Institute of Clinical Sciences, University of Birmingham. L. O’Malley and K. Druce contributed equally to this work.
Address correspondence to Prof. L. Harper, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK. E-mail: L.Harper@bham.ac.uk.
Accepted for publication June 20, 2019.